Non-functioning pituitary adenomas (NFPAs) are benign pituitary neoplasms that do not cause hormonal hypersecretion. They cover up to about half of pituitary adenomas and have a prevalence of 0.7-4 per million in the population. They are mostly seen in the fourth decade. Most NFPAs are asymptomatic. Large ones can cause significant hypothalamic/pituitary dysfunction and visual field distortion 1.

The bones are negatively affected by the deficiency (GH, FSH, LH) and excess (acromegaly, cushing disease, prolactinoma) anterior pituitary hormones 2. The status of bone parameters in patients with non-functioning pituitary adenomas with normal pituitary functions is not clear in the literature.

The Wnt signaling pathway plays an essential role in osteoblast differentiation, proliferation, and activation. Sclerostin, encoded by the SOST gene and synthesized by osteocytes, is a Wnt antagonist. In addition, sclerostin also increases osteoclast activity. High levels of sclerostin negatively affect bone. Therefore, sclerostin antibodies have been used to treat osteoporosis in recent years 3.

This study aimed to investigate serum sclerostin levels in patients with non-functioning pituitary adenoma compared to healthy controls and patients with non-functioning pituitary adenoma to assess the potential relationship between sclerostin and Bone Mineral Density (BMD).